Trevena Inc. (TRVN) announced Monday morning that the FDA has granted a Breakthrough Therapy designation to its intravenous oliceridine, for the management of moderate-to-severe acute pain.
from RTT - Before the Bell http://ift.tt/1QvA3z5
via IFTTT
No comments:
Post a Comment